newsfilter
← Latest News
GlobeNewswire·

Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update

Strong cash position of CHF2.8 million at end of Q1 2025GABAB PAM chronic cough candidate demonstrated robust anti-tussive activity in disease models Regained rights to our phase 2 mGlu2 PAM asset, ADX71149Indivior